The first study on the efficiency of PARPi in breast cancer was conducted by Bryant et al. [13] and Farmer et al. [14] and included women with breast tumors that are not necessarily BRCA1/2 mutated but resemble BRCA-mutated BC such as TNBC phenotypically. Here, BRCA1 is linked to breast neoplasm.